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Abstract
Purpose/Objective: Little is known about the clinical impact of using multiparametric MRI to plan early salvage
radiotherapy after radical prostatectomy. We aimed to evaluate the incidence and location of recurrence based
on pelvic multiparametric MRI findings and to identify clinical variables predictive of positive imaging results.
Materials and methods: We defined radiological criteria of local and lymph node malignancy and reviewed
records and MRI studies of 70 patients with PSA recurrence after radical prostatectomy. We performed univariate
and multivariate analysis to identify any association between clinical, pathological and treatment-related variables
and imaging results.
Results: Multiparametric MRI was positive in 33/70 patients. We found local and lymph node recurrence in 27
patients and 7 patients, respectively, with a median PSA value of 0.38 ng/ml. We found no statistically significant
differences between patients with positive and negative multiparametric MRI for any variable. Shorter PSADT was
associated with positive lymph nodes (median PSADT: 5.12 vs 12.70 months; p: 0.017).
Conclusions: Nearly half the patients had visible disease in multiparametric MRI despite low PSA. Positive
lymph nodes incidence should be considered when planning salvage radiotherapy, particularly in patients
with a short PSADT.
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Introduction
Radical prostatectomy is the gold standard treatment for
localized prostate cancer, but depending on the pathologic
tumor stage, up to 60 % of patients who undergo radical
prostatectomy develop biochemical recurrence and re-
quire further treatment [1]. Salvage radiotherapy is the
only treatment with curative intention for these patients
and has been associated with a three-fold increase in pros-
tate cancer-specific survival when compared with observa-
tion [2]. Despite these good results, around 50 % patients
have recurrence in the ten years after salvage radiotherapy
[3]. Major factors contributing to the high risk of progres-
sion after radiotherapy are: 1) uncertainty about the best
time to perform adjuvant or salvage radiotherapy [4]; 2)
difficulties locating the site of recurrence; 3) the risk of
missing subclinical disease when defining the clinical tar-
get volume (CTV); and 4) the possibility of delivering in-
sufficient radiation dose.
Several studies [5–8] have investigated the accuracy of
endorectal coil MRI for detecting local recurrence after
radical prostatectomy. These studies mostly included
men with mean PSA greater than 1 ng/ml and in many
cases with clinically palpable recurrent disease. More-
over, none of these studies reported results combining
three MRI techniques: T2-weighted imaging, dynamic
contrast enhanced imaging and diffusion weighted im-
aging [8]. The main aim of this study was to evaluate the
incidence and location of visible recurrence of prostate
cancer on pelvic multiparametric MRI (mp-MRI) in men
evaluated for early salvage radiotherapy. We also aimed
to determine the association of clinical and pathological
variables with the imaging results.
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Patients and methods
We performed a retrospective study in patients with
prostate cancer who had biochemical failure after rad-
ical prostatectomy (PSA > 0.2 and increasing) and re-
ceived salvage radiotherapy. Following our protocol,
men referred for the consideration of salvage radiother-
apy underwent an mp-MRI to investigate the site of
recurrence before planning the radiation treatment. Pa-
tients without an mp-MRI study due to a clinical or
technical contraindication were excluded. Surgical
treatment was performed at the urology department at
the hospital Fundación Puigvert and radiotherapy was
carried out at the department of radiation oncology at
the Hospital de la Santa Creu i Sant Pau. We pooled
data from the clinical records of patients included in
the study, and multidisciplinary review board approval
was received from both hospitals participating in the
study.
mp-MRI was performed on a 3-Tesla scanner (Achieva
Medical Systems, Philips) using a surface phase array
SENSE cardiac coil (six channels). MR imaging was ac-
quired under the same conditions as the simulation CT:
the patient in supine position with a knee support, empty
rectum and comfortably full bladder.
The morphological study was obtained with T2-weighted
turbo-spin echo (TSE) sequences in axial, coronal and sa-
gittal planes using the following parameters: TR/TE 4278/
100, 3 mm slice thickness, no gap and 300 FOV.
For functional evaluation, echo-planar diffusion se-
quences (DWI) TR/TE 2193/8, b values of 0, 1000,
1500 s/mm2, 4 mm slice thickness, matrix 140 × 120
were performed Apparent diffusion maps were gener-
ated and ADC (apparent diffusion coefficient values)
were calculated by placing a region of interest (ROI) on
the suspicious area.
Dynamic contrast enhance acquisition (DCE) was
obtained by 3D gradient-echo-fat-suppressed sequence
in the axial plane after injecting the paramagnetic
contrast medium (0,1 ml/Kg Gadoteridol, Prohance,
Bracco Amsterdam); 1,7 mm voxel size; matrix 148 ×
146 and 7 mm dynamic scan time. MRI data process-
ing was performed on a virtual work station (Intelli-
space Portal Phillips Systems V5.02.10011) by two
uroradiologists with more than ten years’ experience,
generating dynamic curves by placing a ROI in sus-
pected areas. The radiologists were blinded to clinical
and pathologic details but were aware of the biochem-
ical failure status.
a
b
Fig. 1 mpMRI malignancy criteria for local recurrence (a) and lymph node (b) recurrence. From left to right: T2-weighted images, DWI and dynamic
contrast enhance image amb curve
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There is no validated scoring system to define a re-
currence after radical prostatectomy on mp-MRI [5].
We used the PI-RADS [6] (Prostate Imaging Report-
ing and Data System for Prostate Cancer Detection
with Multiparametric Magnetic Resonance Imaging)
to define the radiological criteria of recurrence. Our
mp-MRI malignancy criteria for local recurrence were:
a soft tissue nodule in or around the prostatectomy
bed in T2-weigthed images, DWI images based on a
PI-RADS score between 3 and 5 and a DCE showing
an early wash-in and type II and III curves based on
PI-RADS score. We considered a recurrence when either
DWI images or the DCE study showed abnormalities. Ab-
normalities exclusively on T2-weighted images were not
indicative of a positive study. Lymph nodes were consid-
ered pathological when the short axis diameter was longer
than 8 mm, the MRI signal was heterogeneous, the con-
tour was irregular and the PI-RADS classification was 5,
following the same criteria that are used for primary
tumor (Fig. 1).
To investigate possible associations between clinical
and pathological variables and imaging results, we re-
corded the initial PSA, pathological stage, pathological
Gleason score, presence and location of extracapsular
extension, vesicle involvement, margin status, number,
morphology and size of positive margins, lymphatic and
or vascular invasion, surgical modality (open, laparos-
copy or robotic prostatectomy), postoperative PSA,
nadir postoperative PSA, PSA at the time of MRI, and
PSADT.
Radiation treatment
Patients without visible recurrence in the mpMRI re-
ceived salvage, three-dimensional conformal radiother-
apy on pelvic lymph nodes (45 Gy) and prostatectomy
bed (71 Gy). Patients with local recurrence received
the same treatment plus a dose escalation on the
tumor to 75 Gy. Patients with lymph node recurrence
received salvage IMRT on pelvic lymph nodes (52.2 Gy
in 29 fractions at 1.8 Gy/fraction) and the prostatec-
tomy bed (63.80–65.25 Gy at 2.20–2.25 Gy/fraction)
together with a simultaneous integrated boost (SIB) on
the involved lymph nodes (60.9–62.35 in 29 fractions
at 2.10–2.15 Gy/fraction). Androgen deprivation treat-
ment was freely delivered based on the preferences of
the attending physicians. No hormonal treatment was
started before the mp-MRI was performed.
Statistical analyses
We analysed differences in clinical, pathological and
treatment-related variables between patients with posi-
tive and negative MRI studies using the T-test for con-
tinuous variables and the Chi-square test for categorical
variables. Non-parametric tests (Mann-Whitney) were
performed to test the medians of both populations. Logis-
tic regression was performed for the multivariate analyses.
Two-sided P values < 0.05 were considered statistically sig-
nificant. Statistical analyses were performed using IBM-
SPSS Inc, Chicago (USA) software for Windows (V22).
Results
From June 2011 to June 2013, 300 patients with prostate
cancer were referred to our department for radiation
treatment. Of these, 70 patients were referred for salvage
radiotherapy after radical prostatectomy and had under-
gone mp-MRI to investigate the site of recurrence.
The median time to diagnosis of recurrence was
38.8 months (2.39–171.50). Patient characteristics are
shown in Table 1. The median age was 66 years (47–81).
Most patients had pT2c or pT3 tumors and the Gleason
score was greater than 7 in 32 % of patients. More than
70 % of the patients were treated with laparoscopy or ro-
botic surgery and the neuro-vascular bundles were pre-
served in nearly half of them. Forty of 70 patients had
positive surgical margins. Most of these positive margins
were at the apex (17), followed by the right posterior pros-
tate lobe (15). The mp-MR study showed visible disease in
33 out of 70 patients (47 %): local recurrence in 27 pa-
tients and lymph node recurrence in 7 patients (1 patient
had both local and regional recurrence). We did not find
statistically significant differences in clinical, pathologic
and surgery modality variables between patients with posi-
tive and negative MR studies (Table 2).
PSA values and kinetics
Median PSA at diagnosis, median nadir PSA after pros-
tatectomy, and median PSA when the mp-MRI was per-
formed were 7.8, 0.00 and 0.38 ng/ml respectively. The
median PSADT was 11.26 months. No differences were
found in PSA values and PSA kinetics between patients
with positive and negative imaging studies (Table 2).
Patients with local recurrence at the mp-MRI
Most local recurrences occurred at the perianastomotic
site (19;27 %), followed by the right retrovesical (3;4.3 %),
left retrovesical (1;1.5 %), periurethral (1;1.5 %), right sem-
inal vesicle (1;1.5 %), left seminal vesicle (1;1.5 %) and
penile bulb (1;1.5 %) sites. The median maximum diam-
eter of the lesions was 8.5 mm (4.5–21 mm). We were
unable to define a significant association between location
of the local recurrence and any clinical, pathologic or sur-
gery related variable.
Patients with lymph node recurrence in the mp-MRI
mp-MRI detected 14 lymph node recurrences in 7 pa-
tients (10 %). The median time to diagnosis of recur-
rence was 24.3 months (range 2.8–75.4 months). The
mean size of the pathological lymph nodes was 10 mm
Hernandez et al. Radiation Oncology  (2015) 10:262 Page 3 of 8
(range 8–16 mm). They were located in the right exter-
nal iliac (5;7 %), the left external iliac (4;6 %), the right
common iliac (1;1.5 %), the right internal iliac (1;1.5 %)
and the right obturador regions (1;1.5 %). Lymph node
recurrence showed radiological behaviour that was iden-
tical to local recurrence.
Five out of 7 patients with lymph node recurrence had a
pT2c or pT3 tumor. The median PSA was 6.8 ng/ml
(range: 5.45–10.98 ng/ml) before surgery. The median
PSA was 0.45 ng/ml (range: 0.31–8.05 ng/ml) when the
MRI was performed. The seven patients had a PSADT of
less than 12 months. Patients with lymph node recurrence
had a significantly shorter PSADT than those without re-
currence (5.12 vs 12.70 months; (p: 0.017) (Table 3).
Discussion
We aimed to evaluate the incidence and location of re-
currence based on pelvic mp-MRI findings and to iden-
tify clinical variables predictive of positive imaging
results. We found that the incidence of visible tumor in
the mp-MRI was nearly 50 % despite a median PSA of
0.38 ng/ml. The incidence of local recurrence was 38 %
(27/70 patients). Other authors [7–9] have reported an
incidence ranging from 84 to 95 % using endorectal coil
MRI. However, the patients in these series had a PSA
higher than 1 ng/ml and larger lesions, some of which
were clinically palpable by digital rectal examination.
Studies on series of patients with a median PSA between
0.3 and 0.59 ng/ml, using endorectal coil MRI [5, 10] or
pelvic coil [11–13], showed an incidence ranging from 24
to 73 %. These heterogeneous results could be due to the
use of different technical protocols of imaging or to differ-
ent imaging or pathologic criteria of local recurrence.
mp-MRI is the only imaging study recommended by
the European Society of Urogenital Radiology (ESUR)
to evaluate pelvic recurrences when the PSA is low
(0.2–2 ng/ml) [6]. In men with PSA-recurrence below
0.5 ng/ml, CT and bone scan do not usually detect re-
currence, and neither TRUS-guided biopsy of the peria-
nastomotic region nor choline PET-CT have shown to
accurately identify pelvis recurrence [14–17]. The results
of a retrospective study [18] and one meta-analysis [19]
have suggested a higher sensitivity of the choline PET-CT
to identify cancer relapse after radical prostatectomy in
patients with PSADT ≤ 6. Our incidence of nearly 50 %
supports the ESUR recommendation [6] to use mp-MRI
to evaluate men with biochemical failure prior to salvage
radiotherapy.
Regarding location, our results are in line with earlier
reports that found that most local recurrences occurred
in the perianastomotic area and the retrovesical region
[20]. Up to 22 % of recurrences have also been ob-
served occurring at the resection of the vas deferens
[21]. Currently, radiation oncologists plan salvage radi-
ation treatment according to the published guidelines
[20] to define the prostate bed and clinical target vol-
ume. Most patients receive blind salvage radiotherapy
without investigating the exact site of recurrence be-
cause the benefit of planning individualised radiation
treatment based on the results of MRI is still unknown.
However, it has been suggested that the use of these
guidelines misses part of the geographic recurrence in
some cases [22, 23].
Few data are available on the ability of mp-MRI to de-
tect lymph node recurrence, particularly, in patients with
a slight increase of PSA after radical prostatectomy. In
Table 1 Clinical, pathologic and treatment related characteristics
ALL (n = 70)
PSA (ng/ml) (Median) 7.8
Pathologic stage
pT2a/b 11
pT2c 29
pT3a 20
pT3b 10
Lymph nodes (20)
pN0 17
pN1 3
Gleason score
≤ 7 48
> 7 22
Bladder neck involved (67)
Yes 7
No 60
Lymphatic vessel invasion
Yes 4
No 2
Unknown 64
Lymphadenectomy
Yes 20
No 50
Radical prostatectomy
Open 20
Laparoscopy/Robotic 50
Positive margin location
Apex 17
Anterior right prostate lobe 7
Posterior right prostate lobe 15
Anterior left prostate lobe 4
Posterior left prostate lobe 7
Base 1
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our series, despite the low PSA value, the mp-MRI de-
tected 14 lymph node metastases in 7 patients (10 %),
mainly in the external iliac region. Involvement of exter-
nal iliac nodes could be related to the direct pathway of
lymphatic drainage of the prostate along the vas deferens
to the external iliac lymph nodes [21]. Liauw et al. [5] re-
ported an incidence of lymph node recurrence of 5 %, but
they used endorectal coil MRI with a different technical
Table 2 Comparation of clinical, pathological and treatment related variables of patients with positive and negative MRI. Univariate
analysis
ALL MR - MR + P*
n = 70 (%) n = 37 (%) n = 33 (%)
PSA (ng/ml) (median) 7.8 7.8 7.75 0.120
Pathologic stage 0.256
pT2 40 (57) 23 (33) 17 (24)
pT3 30 (43) 14 (20) 16 (23)
Lymph nodes (20) 0.215
pN0 17 (85) 12 (60) 5 (25)
pN1 3 (15) 1 (5) 2 (10)
Gleason score 0.527
≤ 7 48 (68) 25 (35) 23 (33)
> 7 22 (32) 12 (17) 10 (15)
Bladder neck involved (67) 0.382
Yes 7 (10) 3 (4) 4 (6)
No 60 (90) 34 (51) 26 (39)
Lymphatic vessel invasion 0.249
Yes 4 (6) 3 (4) 1 (2)
No 2 (3) 2 (3) 0 (0)
Unknown 64 (91) 32 (45.5) 32 (45.5)
Positive margins 0.510
Yes 40 (57) 21 (30) 19 (27)
No 30 (43) 16 (23) 14 (20)
Lymphadenectomy 0.092
Yes 20 (29) 13 (19) 7 (10)
No 50 (71) 24 (34) 26 (37)
Radical prostatectomy 0.312
Open 20 (29) 12 (17) 8 (12)
Laparoscopy/Robotic 50 (71) 25 (35.5) 25 (35.5)
N-V bundle preservation 0.223
Yes 32 (46) 19 (27) 13 (19)
No 38 (54) 18 (26) 20 (28)
*PSA diagnostic (ng/ml) 0.630
Median 7.77 (3.98–58.63) 7.77 (3.98–58.63) 7.75 (4.1–32)
*Nadir postop PSA (ng/ml) 0.101
Median 0.00 (0.00–6.68) 0.00 (0.00–0.70) 0.01 (0.00–6.68)
*PSA at recurrence (ng/ml) 0.737
Median 0.38 (0.00–8.05) 0.41 (0.00–1.13) 0.37 (0.15–8.05)
*PSADT (months) 0.446
Median 1.62 (0.67–153.24) 14.64 (0.67–49.95) 8.18 (2.48–145.2)
*Median and range. Mann-Whitney Test. *pN1 (lymphadenectomy of 11 lymph nodes)
IPSA: PSA at diagnosis, PSApRP: PSA post radical prostatectomy, PSApreRT: PSA at the MRI, PSADT: PSA doubling time
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protocol. A recent study showed that diffusion-
weighted MRI had an accuracy of 90 % for detecting
lymph nodes smaller than 1 cm [24]. In two investiga-
tional studies [25, 26], other authors who performed
MR lymphography with ferumoxtran-10 have reported
an incidence of 72 and 20 % of positive lymph nodes of
less than 1 cm in patients with biochemical recurrence
after radical prostatectomy even when PSA was low. How-
ever, ferumoxtran-10 is only approved for clinical investi-
gation. Despite these encouraging results, the sensitivity of
the MRI and the 11C-choline PET/CT to detect lymph
node metastases remains equally low [27, 28] even al-
though it has been suggested to be slightly higher for
diffusion-weighted MR [27].
The benefit of whole pelvis irradiation during salvage
RT is controversial [29] but data from retrospective
studies have shown a higher biochemical complete re-
sponse rate [30] and biochemical relapse-free survival
[31] when pelvic lymph nodes are included in the radi-
ation field. One of the factors limiting the benefit of
pelvic radiotherapy could be changes in the pattern of
lymph node spread after radical prostatectomy. This
different distribution of lymph nodes could not be ad-
equately covered by the standard clinical target volume.
In this setting, in one investigational study using
ferumoxtran-10 MRI lymphography, 61 % of patients
with PSA recurrence after radical prostatectomy, had
positive lymph nodes outside the elective clinical target
volume, despite a PSA lower than 1 ng/ml [25]. A recent
retrospective study, that evaluated the usefulness of 11C-
choline PET/TC in 605 patients with early recurrent pros-
tate cancer referred for salvage radiotherapy, showed a
higher incidence of pelvic lymph nodes when the PSADT
was less than 6 months (17.1 vs 2.1 %) [18]. The incidence
of 10 % in our study indicates lymph node recurrence
should be kept in mind when planning salvage radiother-
apy, even when PSA is below 1 ng/ml.
Several points of interest arose when we analysed the
association between clinical factors and mp-MRI find-
ings. When we compared patients with and without
lymph node recurrence in the mp-MRI separately, we
observed a low PSA at recurrence and a statistically sig-
nificant shorter PSADT (median 5.12 vs 12.7 months;
p: 0.017) . These results are in line with other authors
who investigated lymph node spread on MRI lymphog-
raphy using ferumoxtran-10 in patients with biochem-
ical failure after RP (PSADT: 3.86 months) [25]. On the
other hand, Couñago et al.,[12], showed a higher prob-
ability of radiographic local relapse when the PASDT
was over 14 months. It would be interesting to investi-
gate the clinical impact of the lymph node irradiation
in patients who have a short PSADT without positive
lymph nodes in the mp-MRI. Alternatively, it could be
advisable to irradiate only the lymph node areas in pa-
tients with positive lymph recurrence in the mp-MRI
and no visible tumor in the prostate bed or high-risk
factors of local recurrence.
Our findings regarding pathologic positive margins
differ from those reported by Verma et al. who ob-
served that radiological recurrence was three times
more likely when surgical margins were involved by
tumor. Although we observed an association between
the PSA at recurrence and MRI findings with a trend
towards a significance, we were unable to define a PSA
cut-off as a predictor of positive MRI. Other authors,
however , have reported a pre-RT cut-off value of >0.3
[5], >0.5 [12] and ≥ 0.54 ng/ml [11] as a predictor of
positive DCE-MRI.
Our study has several limitations. It was a retrospect-
ive analysis of a relatively small number of patients and
the radiologists were not totally blinded to clinical in-
formation. Our results are based exclusively on radio-
logical findings and we lack histological confirmation of
local or nodal recurrences. Nevertheless, radiological
and pathological correlations have been established in
treatment-naive patients with prostate cancer [24]. The
strengths of this study are that all mp-MRI were per-
formed at the same department and were all analysed
by two expert uroradiologists who defined the radiology
criteria of malignancy before starting the review of the
studies.
In view of the results, we have slightly modified our
current imaging protocol. We have widened pelvic size
for the DCE-MRI and DW sequences to ensure the
functional study encompass lymph nodes in the highest
region of the pelvis. These patients have been treated
under a protocol of dose escalation on visible recurrence
which will allow us to analyse its clinical impact.
Table 3 PSA values and kinetics for patients with and without
lymph node recurrence
MR Median Range p-value
PSA* (diagnosis) 0.628
N+ 6.80 5.17–25
N 8.12 3.98–58.63
Nadir post-op PSA* 0.560
N+ 0.02 0.00–2.63
N 0.002 0.00–32.50
PSA* (recurrence) 0.102
N+ 0.49 0.31–8.05
N 0.36 0.00–32.50
PSADT** 0.017
N+ 5.12 2.58–11.52
N 12.70 1.98–153.24
Median and range. Mann-Whitney Test; *ng/ml, ** PSA doubling time (months)
N+ positive lymph nodes in the MRI, N- negative lymph nodes in the MRI
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Conclusion
Our results support the use of mp-MRI to plan salvage
radiotherapy after radical prostatectomy, even in patients
with low PSA levels. Positive lymph nodes incidence
should be considered, particularly in patients with a short
PSADT.
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